IP Library › Granted Patent US 12,415,798
Granted Patent B2
US 12,415,798 · App. 17/899,672 · Granted Sep 16, 2025

Processes for making modulators of cystic fibrosis transmembrane conductance regulator

Inventors: Paul T. Angell (Carlsbad, CA); Cristian Harrison (Beverly, MA); Robert M. Hughes (San Diego, CA); Berenice Lewandowski (Braintree, MA); Benjamin J. Littler (Carlsbad, CA); Vito Melillo (Escondido, CA); William A. Nugent (Noblesville, IN); David Andrew Siesel (San Diego, CA); David Smith (Newton, MA); John Studley (Witney, GB)
Assignee: Vertex Pharmaceuticals Incorporated
C07D401/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,415,798
App. No.
17/899,672
Granted
Sep 16, 2025
Kind
B2
Abstract

The disclosure provides processes for preparing a compound of Formula (I):

Claims (9)

1. A compound of Formula viii:

Compound 6

a salt or deuterated derivative thereof, wherein

R 1 is a protecting group; and

R b is C 1 -C 4 alkyl.

2. The compound, salt, or deuterated derivative according to claim 1 , wherein R 1 is t-butyl carbamate (Boc), benzyl (Bn), tetrahydropyranyl (THP), 9-fluorenylmethyl carbamate (Fmoc), benzyl carbamate (Cbz), acetamide, trifluoroacetamide, triphenylmethylamine, benzylideneamine, and p-toluenesulfonamide.

3. The compound, salt, or deuterated derivative according to claim 1 , wherein R 1 is t-butyl carbamate (Boc), benzyl (Bn), and tetrahydropyranyl (THP).

4. The compound, salt, or deuterated derivative according to claim 1 , wherein R 1 is t-butyl carbamate (Boc).

5. The compound, salt, or deuterated derivative according to claim 1 , wherein R b is ethyl.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2025
From: SIESEL, DAVID ANDREW
To: VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
Reel/Frame 072047/0308 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2025
From: VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 072047/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2025
From: LITTLER, BENJAMIN J.
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 072047/0353 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2025
From: STUDLEY, JOHN
To: VERTEX PHARMACEUTICALS (EUROPE) LIMITED
Reel/Frame 072047/0357 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2025
From: HUGHES, ROBERT M.
To: VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
Reel/Frame 072047/0454 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2025
From: SIESEL, DAVID ANDREW; ANGELL, PAUL T.
To: VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
Reel/Frame 072047/0458 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2025
From: LITTLER, BENJAMIN J.; MELILLO, VITO; HARRISON, CRISTIAN; LEWANDOWSKI, BERENICE; NUGENT, WILLIAN A.; SMITH, DAVID
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 072047/0520 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2025
From: VERTEX PHARMACEUTICALS (EUROPE) LIMITED
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 072047/0557 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2025
From: VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 072047/0561 →
Continuity (5)
Division 16769047
Provisional Application 62649970 · Mar 29, 2018
Provisional Application 62623725 · Jan 30, 2018
Provisional Application 62596452 · Dec 8, 2017
Related Publication 20240025877A1 · Jan 25, 2024
References Cited (387)
US 5410061A · Gilmore et al. · 1995 [cited by applicant]
US 6441004B1 · Faull et al. · 2002 [cited by applicant]
US 6787651B2 · Stolle et al. · 2004 [cited by applicant]
US 6949572B2 · Bertinato et al. · 2005 [cited by applicant]
US 6979692B2 · Bertinato et al. · 2005 [cited by applicant]
US 7368573B2 · Bertinato et al. · 2008 [cited by applicant]
US 8058299B2 · Bolin et al. · 2011 [cited by applicant]
US 9663508B2 · Bregman et al. · 2017 [cited by applicant]
US 9782408B2 · Miller et al. · 2017 [cited by applicant]
US 9981910B2 · Altenbach et al. · 2018 [cited by applicant]
US 10118916B2 · Altenbach et al. · 2018 [cited by applicant]
US 10131670B2 · Strohbach et al. · 2018 [cited by applicant]
US 10138227B2 · Altenbach et al. · 2018 [cited by applicant]
US 10208053B2 · Strohbach et al. · 2019 [cited by applicant]
US 10258624B2 · Miller et al. · 2019 [cited by applicant]
US 10570115B2 · Alcacio et al. · 2020 [cited by applicant]
US 10654829B2 · Dhamankar et al. · 2020 [cited by applicant]
US 10758534B2 · Miller et al. · 2020 [cited by applicant]
US 10793547B2 · Abela et al. · 2020 [cited by applicant]
US 11155533B2 · Dhamankar et al. · 2021 [cited by applicant]
US 11179367B2 · Chu et al. · 2021 [cited by applicant]
US 11186566B2 · Alcacio et al. · 2021 [cited by applicant]
US 11253509B2 · Chen et al. · 2022 [cited by applicant]
US 11414439B2 · Abela et al. · 2022 [cited by applicant]
US 11426407B2 · Miller et al. · 2022 [cited by applicant]
US 11434201B2 · Angell et al. · 2022 [cited by applicant]
US 11453655B2 · Abela et al. · 2022 [cited by applicant]
US 11465985B2 · Angell et al. · 2022 [cited by applicant]
US 11517564B2 · Chen et al. · 2022 [cited by applicant]
US 20020055631A1 · Augeri et al. · 2002 [cited by applicant]
US 20020086887A1 · Augeri et al. · 2002 [cited by applicant]
US 20040006237A1 · Dolitzky et al. · 2004 [cited by applicant]
US 20050171185A1 · Yamasaki et al. · 2005 [cited by applicant]
US 20050197376A1 · Kayakiri et al. · 2005 [cited by applicant]
US 20070105833A1 · Ruah et al. · 2007 [cited by applicant]
US 20100160322A1 · Bruncko et al. · 2010 [cited by applicant]
US 20100227888A1 · Hadida Ruah et al. · 2010 [cited by applicant]
US 20110165118A1 · Chan et al. · 2011 [cited by applicant]
US 20130072483A1 · Wenge et al. · 2013 [cited by applicant]
US 20130267493A1 · Bhattacharya et al. · 2013 [cited by applicant]
US 20130317000A1 · Chowdhury et al. · 2013 [cited by applicant]
US 20130317001A1 · Andrez et al. · 2013 [cited by applicant]
US 20140080825A1 · Hadida-Ruah et al. · 2014 [cited by applicant]
US 20140296200A1 · Brown et al. · 2014 [cited by applicant]
US 20150320736A1 · Phenix et al. · 2015 [cited by applicant]
US 20150322002A1 · Dehnhardt et al. · 2015 [cited by applicant]
US 20160098585A1 · Sempere et al. · 2016 [cited by applicant]
US 20180099932A1 · Altenbach et al. · 2018 [cited by applicant]
US 20180141954A1 · Strohbach et al. · 2018 [cited by applicant]
US 20180170938A1 · Strohbach et al. · 2018 [cited by applicant]
US 20180244611A1 · Altenbach et al. · 2018 [cited by applicant]
US 20180244640A1 · Altenbach et al. · 2018 [cited by applicant]
US 20190055220A1 · Bear et al. · 2019 [cited by applicant]
US 20190077784A1 · Altenbach et al. · 2019 [cited by applicant]
US 20190153000A1 · Munoz et al. · 2019 [cited by applicant]
US 20190240197A1 · Chu et al. · 2019 [cited by applicant]
US 20190269683A1 · Miller et al. · 2019 [cited by applicant]
US 20200171015A1 · Haseltine et al. · 2020 [cited by applicant]
US 20210032272A1 · Abela et al. · 2021 [cited by applicant]
US 20210069174A1 · Chu et al. · 2021 [cited by applicant]
US 20210113547A1 · Chen et al. · 2021 [cited by applicant]
US 20210139514A1 · Abela et al. · 2021 [cited by applicant]
US 20210228489A1 · Dokou et al. · 2021 [cited by applicant]
US 20220257564A1 · Chu et al. · 2022 [cited by applicant]
US 20220306606A1 · Alcacio et al. · 2022 [cited by applicant]
US 20230233560A1 · Miller et al. · 2023 [cited by applicant]
US 20230241045A1 · Chen et al. · 2023 [cited by applicant]
AU 2013231151A1 · 2013 [cited by applicant]
AU 2013270464A1 · 2014 [cited by applicant]
CA 2145473A1 · 1995 [cited by applicant]
CN 101087781A · 2007 [cited by applicant]
CN 102458122A · 2012 [cited by applicant]
CN 103946221A · 2014 [cited by applicant]
EA 011074B1 · 2008 [cited by applicant]
EA 28378B1 · 2017 [cited by applicant]
EP 0194599A2 · 1986 [cited by applicant]
EP 0673930A1 · 1995 [cited by applicant]
EP 1318978B1 · 2006 [cited by applicant]
GB 967177A · 1964 [cited by applicant]
IN 201917015614 · 2019 [cited by applicant]
IN 201917024177 · 2019 [cited by applicant]
JP 10114654A · 1998 [cited by applicant]
JP 2007511530A · 2007 [cited by applicant]
JP 2008524233A · 2008 [cited by applicant]
JP 2011520785A · 2011 [cited by applicant]
KR 1020050061501A · 2005 [cited by applicant]
RU 2463303C2 · 2012 [cited by applicant]
RU 2608610C2 · 2017 [cited by applicant]
TW 201713617A · 2017 [cited by applicant]
WO WO9603380A1 · 1996 [cited by applicant]
WO WO9622022A1 · 1996 [cited by applicant]
WO WO9718712A1 · 1997 [cited by applicant]
WO WO9722586A1 · 1997 [cited by applicant]
WO WO9808818A1 · 1998 [cited by applicant]
WO WO9831226A1 · 1998 [cited by applicant]
WO WO9907351A2 · 1999 [cited by applicant]
WO WO9916744A1 · 1999 [cited by applicant]
WO WO9937153A1 · 1999 [cited by applicant]
WO WO9941238A1 · 1999 [cited by applicant]
WO WO0076969A1 · 2000 [cited by applicant]
WO WO0108487A1 · 2001 [cited by applicant]
WO WO0115533A1 · 2001 [cited by applicant]
WO WO0139597A2 · 2001 [cited by applicant]
WO WO0215902A1 · 2002 [cited by applicant]
WO WO0224636A2 · 2002 [cited by applicant]
WO WO0230895A1 · 2002 [cited by applicant]
WO WO02085120A2 · 2002 [cited by applicant]
WO WO02096883A1 · 2002 [cited by applicant]
WO WO03002533A1 · 2003 [cited by applicant]
WO WO03022050A1 · 2003 [cited by applicant]
WO WO03028458A1 · 2003 [cited by applicant]
WO WO03043423A1 · 2003 [cited by applicant]
WO WO03043655A1 · 2003 [cited by applicant]
WO WO03101959A1 · 2003 [cited by applicant]
WO WO03103394A2 · 2003 [cited by applicant]
WO WO2004021788A1 · 2004 [cited by applicant]
WO WO2004021987A2 · 2004 [cited by applicant]
WO WO2004037798A1 · 2004 [cited by applicant]
WO WO2004039753A2 · 2004 [cited by applicant]
WO WO2004043939A1 · 2004 [cited by applicant]
WO WO2004046141A1 · 2004 [cited by applicant]
WO WO2004056775A1 · 2004 [cited by applicant]
WO WO2004056777A1 · 2004 [cited by applicant]
WO WO2004078114A2 · 2004 [cited by applicant]
WO WO2004085420A1 · 2004 [cited by applicant]
WO WO2004111014A1 · 2004 [cited by applicant]
WO WO2005049018A1 · 2005 [cited by applicant]
WO WO2005054191A1 · 2005 [cited by applicant]
WO WO2005070006A2 · 2005 [cited by applicant]
WO WO2005075435A1 · 2005 [cited by applicant]
WO WO2005080373A1 · 2005 [cited by applicant]
WO WO2005085216A1 · 2005 [cited by applicant]
WO WO2005099705A2 · 2005 [cited by applicant]
WO WO2005108369A1 · 2005 [cited by applicant]
WO WO2006002421A2 · 2006 [cited by applicant]
WO WO2006030807A1 · 2006 [cited by applicant]
WO WO2006039212A2 · 2006 [cited by applicant]
WO WO2006065204A1 · 2006 [cited by applicant]
WO WO2006066968A1 · 2006 [cited by applicant]
WO WO2006067392A2 · 2006 [cited by applicant]
WO WO2007019397A2 · 2007 [cited by applicant]
WO WO2007021982A2 · 2007 [cited by applicant]
WO WO2007053641A2 · 2007 [cited by applicant]
WO WO2007075946A1 · 2007 [cited by applicant]
WO WO2007079139A2 · 2007 [cited by applicant]
WO WO2007087066A2 · 2007 [cited by applicant]
WO WO2007113327A2 · 2007 [cited by applicant]
WO WO2007117715A2 · 2007 [cited by applicant]
WO WO2007134279A2 · 2007 [cited by applicant]
WO WO2008005457A2 · 2008 [cited by applicant]
WO WO2008100867A2 · 2008 [cited by applicant]
WO WO2008127399A2 · 2008 [cited by applicant]
WO WO2008141385A1 · 2008 [cited by applicant]
WO WO2009006315A1 · 2009 [cited by applicant]
WO WO2009027730A1 · 2009 [cited by applicant]
WO WO2009032116A1 · 2009 [cited by applicant]
WO WO2009038683A2 · 2009 [cited by applicant]
WO WO2009064848A1 · 2009 [cited by applicant]
WO WO2009071947A2 · 2009 [cited by applicant]
WO WO2009073757A1 · 2009 [cited by applicant]
WO WO2009076142A2 · 2009 [cited by applicant]
WO WO2009127822A2 · 2009 [cited by applicant]
WO WO2009138758A2 · 2009 [cited by applicant]
WO WO2010003444A2 · 2010 [cited by applicant]
WO WO2010007116A2 · 2010 [cited by applicant]
WO WO2010019239A2 · 2010 [cited by applicant]
WO WO2010022307A2 · 2010 [cited by applicant]
WO WO2010025295A2 · 2010 [cited by applicant]
WO WO2010048526A2 · 2010 [cited by applicant]
WO WO2010053471A1 · 2010 [cited by applicant]
WO WO2010054138A2 · 2010 [cited by applicant]
WO WO2010065824A2 · 2010 [cited by applicant]
WO WO2010078103A1 · 2010 [cited by applicant]
WO WO2010083441A2 · 2010 [cited by applicant]
WO WO2010102758A2 · 2010 [cited by applicant]
WO WO2010108155A1 · 2010 [cited by applicant]
WO WO2010108162A1 · 2010 [cited by applicant]
WO WO2010110231A1 · 2010 [cited by applicant]
WO WO2010123822A1 · 2010 [cited by applicant]
WO WO2010138588A2 · 2010 [cited by applicant]
WO WO2011019413A1 · 2011 [cited by applicant]
WO WO2011068560A1 · 2011 [cited by applicant]
WO WO2011072241A1 · 2011 [cited by applicant]
WO WO2011102514A1 · 2011 [cited by applicant]
WO WO2011113894A1 · 2011 [cited by applicant]
WO WO2011116397A1 · 2011 [cited by applicant]
WO WO2011119984A1 · 2011 [cited by applicant]
WO WO2011127241A2 · 2011 [cited by applicant]
WO WO2011127290A2 · 2011 [cited by applicant]
WO WO2011128251A1 · 2011 [cited by applicant]
WO WO2011133751A2 · 2011 [cited by applicant]
WO WO2011133951A1 · 2011 [cited by applicant]
WO WO2011150016A1 · 2011 [cited by applicant]
WO WO2012027247A2 · 2012 [cited by applicant]
WO WO2012027731A2 · 2012 [cited by applicant]
WO WO2012052540A1 · 2012 [cited by applicant]
WO WO2012087938A1 · 2012 [cited by applicant]
WO WO2012089721A1 · 2012 [cited by applicant]
WO WO2012089722A2 · 2012 [cited by applicant]
WO WO2012102297A1 · 2012 [cited by applicant]
WO WO2012110519A1 · 2012 [cited by applicant]
WO WO2012116960A1 · 2012 [cited by applicant]
WO WO2012139891A1 · 2012 [cited by applicant]
WO WO2012166415A1 · 2012 [cited by applicant]
WO WO2012170061A1 · 2012 [cited by applicant]
WO WO2013033068A1 · 2013 [cited by applicant]
WO WO2013037955A1 · 2013 [cited by applicant]
WO WO2013038373A1 · 2013 [cited by applicant]
WO WO2013041602A1 · 2013 [cited by applicant]
WO WO2013070961A1 · 2013 [cited by applicant]
WO WO2013082102A1 · 2013 [cited by applicant]
WO WO2013112804A1 · 2013 [cited by applicant]
WO WO2013118805A1 · 2013 [cited by applicant]
WO WO2013130669A1 · 2013 [cited by applicant]
WO WO2013158121A1 · 2013 [cited by applicant]
WO WO2013177224A1 · 2013 [cited by applicant]
WO WO2013185112A1 · 2013 [cited by applicant]
WO WO2013185202A1 · 2013 [cited by applicant]
WO WO2014008458A2 · 2014 [cited by applicant]
WO WO2014014841A1 · 2014 [cited by applicant]
WO WO2014017093A1 · 2014 [cited by applicant]
WO WO2014028381A1 · 2014 [cited by applicant]
WO WO2014028968A1 · 2014 [cited by applicant]
WO WO2014039714A2 · 2014 [cited by applicant]
WO WO2014047427A2 · 2014 [cited by applicant]
WO WO2014071122A1 · 2014 [cited by applicant]
WO WO2014071247A1 · 2014 [cited by applicant]
WO WO2014071378A1 · 2014 [cited by applicant]
WO WO2014086723A1 · 2014 [cited by applicant]
WO WO2014086739A1 · 2014 [cited by applicant]
WO WO2014086751A1 · 2014 [cited by applicant]
WO WO2014096388A2 · 2014 [cited by applicant]
WO WO2014109858A1 · 2014 [cited by applicant]
WO WO2014144100A2 · 2014 [cited by applicant]
WO WO2014152013A1 · 2014 [cited by applicant]
WO WO2014152018A1 · 2014 [cited by applicant]
WO WO2014180562A1 · 2014 [cited by applicant]
WO WO2014181287A1 · 2014 [cited by applicant]
WO WO2014190199A1 · 2014 [cited by applicant]
WO WO2015010832A1 · 2015 [cited by applicant]
WO WO2015031608A1 · 2015 [cited by applicant]
WO WO2015052264A1 · 2015 [cited by examiner]
WO WO2015069287A1 · 2015 [cited by applicant]
WO WO2015073231A1 · 2015 [cited by applicant]
WO WO2015160787A1 · 2015 [cited by applicant]
WO WO2016057730A1 · 2016 [cited by applicant]
WO WO2016057572A1 · 2016 [cited by applicant]
WO WO2016081556A1 · 2016 [cited by applicant]
WO WO2016105484A1 · 2016 [cited by applicant]
WO WO2016105485A2 · 2016 [cited by applicant]
WO WO2016128529A1 · 2016 [cited by applicant]
WO WO2016160945A1 · 2016 [cited by applicant]
WO WO2017053455A1 · 2017 [cited by applicant]
WO WO2017172802A1 · 2017 [cited by applicant]
WO WO2017173274A1 · 2017 [cited by applicant]
WO WO2017177124A1 · 2017 [cited by applicant]
WO WO2017187321A1 · 2017 [cited by applicant]
WO WO2017223188A1 · 2017 [cited by applicant]
WO WO2018064632A1 · 2018 [cited by applicant]
WO WO2018081377A1 · 2018 [cited by applicant]
WO WO2018081378A1 · 2018 [cited by applicant]
WO WO2018081381A1 · 2018 [cited by applicant]
WO WO2018107100A1 · 2018 [cited by applicant]
WO WO2018116185A1 · 2018 [cited by applicant]
WO WO2018127130A1 · 2018 [cited by applicant]
WO WO2018183367A1 · 2018 [cited by applicant]
WO WO2018201126A1 · 2018 [cited by applicant]
WO WO2018227049A1 · 2018 [cited by applicant]
WO WO2019010092A1 · 2019 [cited by applicant]
WO WO2019018353A1 · 2019 [cited by applicant]
WO WO2019018395A1 · 2019 [cited by applicant]
WO WO2019028228A1 · 2019 [cited by applicant]
WO WO2019071078A1 · 2019 [cited by applicant]
WO WO2019079760A1 · 2019 [cited by applicant]
WO WO2019113089A1 · 2019 [cited by applicant]
WO WO2019113476A1 · 2019 [cited by applicant]
WO WO2019152940A1 · 2019 [cited by applicant]
WO WO2019026075A1 · 2019 [cited by applicant]
WO WO2019191620A1 · 2019 [cited by applicant]
WO WO2019195739A1 · 2019 [cited by applicant]
WO WO2019200246A1 · 2019 [cited by applicant]
WO WO2020214921A1 · 2020 [cited by applicant]
WO WO2020242935A1 · 2020 [cited by applicant]
WO WO2021030552A1 · 2021 [cited by applicant]
WO WO2021030554A1 · 2021 [cited by applicant]
WO WO2021030555A1 · 2021 [cited by applicant]
WO WO2021030556A1 · 2021 [cited by applicant]
Anilkumar, G.N. et al. (2011) “II. Novel HCV NS5B polymerase inhibitors: Discovery of indole C2 acyl sulfonamides” [cited by applicant]
Atzrodt J, Derdau V, Fey T, Zimmermann J. “The Renaissance of H/D Exchange” Angew. Chem. Int. Ed. 2007: 46, 7744-7765. [cited by applicant]
Atzrodt J, Derdau V, Kerr W, Reid M. “C—H functionalization for hydrogen isotope exchange” Angew. Chem. Int. Ed. 2018: 57, 3022-3047. [cited by applicant]
Belikov, V.G., (2007) [cited by applicant]
Bhattacharya, S. et al. (2009) Polymorphism in Pharmaceutical Solids: Thermoanalytical and Crystallographic Methods (Brittain H. ed., 2d ed. Informa Healthcare USA, Inc. 2009) 318-335. [cited by applicant]
Borhade, S.R. et al. (2013) “Synthesis of Novel Aryl and Heteroaryl Acyl Sulfonimidamides via Pd-Catalyzed Carbonylation Using a Nongaseous Precursor” [cited by applicant]
Boyle, M. “A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial,” The Lancet Respirato… [cited by applicant]
Braman, V.; Liu, J. F.; Harbeson, S.; Uttamsingh, V.; Bridson, G.; Wu, L.; Shipley, J. E. “Preliminary Clinical Outcomes for CTP-354, a Novel Subtype-Selective GABA(A) Modulator” Presented at the American Neurological A… [cited by applicant]
Brown et al. (2006) “On scaffolds and hopping in medicinal Chemistry,” Mini-reviews in medicinal chemistry, vol. 6, 11(13), 1217-1229. [cited by applicant]
Byrn, S. et al. (1995) “Pharmaceutical solids: A strategic approach to regulatory considerations,” (12): 945-954. [cited by applicant]
Caira, M. R. (1998) “Crystalline Polymorphism of Organic Compounds,” [cited by applicant]
Cargnin S, Serafini M, Pirali T. “A primer of deuterium in drug design” Future Med. Chem. 2019; 11(16): 2039-2042. [cited by applicant]
Chemical Abstracts Service, CAS Registry No. 204017-11-8. CA Index Name: 1H-Indole-2-carboxamide, 1-[[2,4-bis(trifluoromethyl)phenyl]methyl]-2,3-dihydro-N-(phenylsulfonyl)-. Entered STN: Apr. 12, 1998. [cited by applicant]
Chemical Abstracts Service, CAS Registry No. 220678-97-7. CA Index Name: 1H-Indole-2-carboxamide, 1-[(3,4-dichlorophenyl)methyl]-N-(phenylsulfonyl)-. Entered STN: Mar. 24, 1999. [cited by applicant]
Chemical Abstracts Service, CAS Registry No. 220678-99-9. CA Index Name: 1H-Indole-2-carboxamide, 1-[(3,4-dichlorophenyl)methyl]-N-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-. Entered STN: Mar. 24, 1999. [cited by applicant]
Chemical Abstracts Service, CAS Registry No. 412005-98-2. CA Index Name: 1H-Indole-2-carboxamide, 3-(4-methoxyphenyl)-N-(phenylsulfonyl)-1-[[3-(trifluoromethyl)phenyl]methyl]-. Entered STN: May 7, 2002. [cited by applicant]
Chemical Abstracts Service, CAS Registry No. 895575-67-4. CA Index Name: 1H-Indole-2-carboxamide, 1-[(3-chlorophenyl)methyl]-4-nitro-N-(2-thienylsulfonyl)-. Jun. 30, 2006. [cited by applicant]
Chemical Abstracts Service, CAS Registry No. 895575-68-5. CA Index Name: 1H-Indole-2-carboxamide, 4-amino-1-[(3-chlorophenyl)methyl]-N-(2-thienylsulfonyl)-. Jul. 23, 2006. [cited by applicant]
Chen, Y. (Jan. 2, 20166) “ [cited by applicant]
Czeskis B, Elmore, CS, Haight A, Hesk D, Maxwell BD, Miller SA, Raglione T, Schildknegt K, Traverse JF, Wang P. “Deuterated active pharmaceutical ingredients: A science-based proposal for synthesis, analysis, and contro… [cited by applicant]
Dao HT, Li C, Michaudel Q, Maxwell BD, Baran PS. J. Am. Chem. Soc. 2015; 137, 8046-8049. [cited by applicant]
Database Caplus, Accession No. 1965:51408. Abstract of French Patent No. FR M2868, filed Nov. 23, 1964, by Roussel-Uclaf [online]. Retrieved Jan. 6, 2017 (1 page). [cited by applicant]
Database Caplus, Accession No. 1965:51409. Abstract of German Patent No. DE 1182243, filed Nov. 26, 1964, by Badische Anilin & Soda-Fabrik A.G. [online]. Retrieved Jan. 6, 2017 (2 pages). [cited by applicant]
Database ChemSpider, CSID:17283620 (CAS: RN 1026625-71-7), http://www.chemspider.com/Chemical-Structure.17283620.html (accessed 16:40, Mar. 30, 2023). [cited by applicant]
Database Pubchem, CID: 44419393. Compound Summary, [cited by applicant]
Database Pubchem, CID: 49774135. Compound Summary, [cited by applicant]
Database Pubchem, CID: 58132855. Compound Summary, [cited by applicant]
Database Pubchem, CID: 20050716. Compound Summary, 1-[2-[[2-[(2- [cited by applicant]
Database Pubchem, CID: 20091118. Compound Summary, [4-(5- [cited by applicant]
Database Pubchem, CID: 20120819. Compound Summary, 4-( [cited by applicant]
Database Pubchem, CID: 2545578. Compound Summary, [cited by applicant]
Dorwald, F. A. (2006) “Side Reactions in Organic Synthesis” Wiley: VCH, Weinheim p. IX of Preface p. 1-15. [cited by applicant]
European Patent Application No. 15849396.5 (Patent No. 3203840): Notice of Opposition by Elkington and Fife, LLP, May 5, 2021 (19 pages). [cited by applicant]
Gant TG. “Using Deuterium in Drug Discovery: Leaving the Label in the Drug” J Med. Chem. 2014; 57(9): 3595-3611. [cited by applicant]
Garg, V. et al. “Pharmacokinetic and Drug-Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor”, Clinical and Translational Science—CTS, vol. 12, No. 3, Jan. 29, 2019 (Jan. 29, 2019), pp. 267-275, XP0557… [cited by applicant]
Ghose et al. (1999) Knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery—qualitive and quantitative characterization of known drug databases, [cited by applicant]
Halford B. “The deuterium switcheroo” Chemical & Engineering News 2016; 94(27), 32-36. [cited by applicant]
Hopkins, C.R. et al. (2006) “Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis” Bioorganic & Medicinal Chemist… [cited by applicant]
International Patent Application No. PCT/US2018/064522: International Search Report and Written Opinion, mailed Jun. 25, 2019 (21 pages). [cited by applicant]
International Patent Application No. PCT/US2015/54316: International Search Report and Written Opinion, mailed Feb. 5, 2016 (11 pages). [cited by applicant]
International Patent Application No. PCT/US2017/025381: International Search Report and Written Opinion, mailed Jun. 6, 2017 (11 pages). [cited by applicant]
International Patent Application No. PCT/US2017/054611: International Search Report and Written Opinion, mailed Jan. 3, 2018 (10 pages). [cited by applicant]
International Patent Application No. PCT/US2017/065425: International Search Report and Written Opinion, mailed Feb. 27, 2018 (10 pages). [cited by applicant]
International Patent Application No. PCT/US2018/036610: International Search Report and Written Opinion, mailed Sep. 19, 2018 (9 pages). [cited by applicant]
International Patent Application No. PCT/US2018/040427: International Search Report and Written Opinion, mailed Oct. 9, 2018 (15 pages). [cited by applicant]
International Patent Application No. PCT/US2018/042415: International Search Report and Written Opinion, mailed Oct. 31, 2018 (12 pages). [cited by applicant]
International Patent Application No. PCT/US2018/042486: International Search Report and Written Opinion, mailed Nov. 7, 2018 (13 pages). [cited by applicant]
International Patent Application No. PCT/US2018/044963: International Search Report and Written Opinion, mailed Sep. 25, 2018 (15 pages). [cited by applicant]
International Patent Application No. PCT/US2018/056772: International Search Report and Written Opinion, mailed Jan. 29, 2019 (13 pages). [cited by applicant]
International Patent Application No. PCT/US2018/063871: International Search Report and Written Opinion, mailed Feb. 25, 2019 (16 pages). [cited by applicant]
International Patent Application No. PCT/US2019/016537: International Search Report and Written Opinion, mailed Apr. 23, 2019 (13 pages). [cited by applicant]
International Patent Application No. PCT/US2019/018042: International Search Report and Written Opinion, mailed Apr. 17, 2019 (10 pages). [cited by applicant]
International Patent Application No. PCT/US2019/024890: International Search Report and Written Opinion, mailed Jun. 17, 2019 (13 pages). [cited by applicant]
International Patent Application No. PCT/US2019/026075: International Search Report and Written Opinion, mailed Jun. 17, 2019 (13 pages). [cited by applicant]
International Patent Application No. PCT/US2019/027202: International Search Report and Written Opinion, mailed Jun. 17, 2019 (10 pages). [cited by applicant]
International Patent Application No. PCT/US2020/028699: International Search Report and Written Opinion, mailed Jul. 20, 2020 (9 pages). [cited by applicant]
International Patent Application No. PCT/US2020/034199: International Search Report and Written Opinion, mailed Aug. 11, 2020 (15 pages). [cited by applicant]
Ivanisevic, I. (2011) “Uses of X-Ray Powder Diffraction in the Pharmaceutical Industry,” Pharm. Form. Qual. 30-33. [cited by applicant]
Jain, B.C. et al. (1947) “Studies in Sulphanilamides. Part XIII. Reaction With Dicarboxylic Acids. Some New N1- and N4-ACYL and Heterocyclic Derivatives” [cited by applicant]
Kettle, J.G. et al. (2004) “N-Benzylindole-2-carboxylic acids: potent functional antagonists of the CCR2b chemokine receptor” [cited by applicant]
Kieltsch, I. et al. Laureates: Awards and Honors SCS Fall Meeting 2007 260 Recent Advances in Electrophilic CF 3—Transfer Using Hypervalent lodine(III) Reagents 11, A Chimia Chimia Schweizerische Chemische Gesellschaft … [cited by applicant]
Kholodov, L.E. et al., Klinicheskaya farmakokinetika (Clinical Pharmacokinetics), M., Meditsina, 1985, pp. 83-98, 134-138, 160, 378-380. [cited by applicant]
Kola et al. (2004) “Can the pharmaceutical industry reduce attrition rates?” Nature Reviews Drug Discovery, 3(8), 711-715. [cited by applicant]
Kratkiy kurs molekulyarnoy biologii (A Concise Course in Molecular Biology), edited by P.V. Sergeev, M., 1975, p. 10. [cited by applicant]
Lai, J.T. et al. (1980) “Rearrangement of 2,2,6,6-tetramethyl-4-piperidone in phase-transfer catalyzed reactions,” [cited by applicant]
Liu, J. F. et al. “CTP-354: A Novel Deuterated Subtype-Selective GABA(A) Modulator for Treatment of Neuropathic Pain, Spasticity and Anxiety Disorders” Presented at the American College of Neuropsychopharmacology (ACNP)… [cited by applicant]
Matter, H. et al. (2002) “Design and Quantitative Structure—Activity Relationship of 3-Amidinobenzyl-1H-indole-2-carboxamides as Potent, Nonchiral, and Selective Inhibitors of Blood Coagulation Factor Xa” [cited by applicant]
Maxwell BD, Tran SB, Lago M, Li J, and Bonacorsi Jr SJ. “The syntheses of [14C]BMS-823778 for use in a human ADME clinical study and of [13CD313CD2]BMT-094817, a stable-isotope labeled standard of a newly detected human… [cited by applicant]
Montemayor, Kristina et al. “Unmasking catamenial hemoptysis in the era of CFTR modulator therapy”, Journal of Cystic Fibrosis, Elsevier, NL, vol. 19, No. 4, Jan. 24, 2020 (Jan. 24, 2020), XP086202454, ISSN: 1569-1993, … [cited by applicant]
NCT03029455 “A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis”. Vertex Pharmaceuticals Incorporated, Retrieved from the Internet: https://clinicaltrials.go… [cited by applicant]
Norman, P. (2014) “Novel picolinamide-based cystic fibrosis transmembrane regulator modulators: evaluation of WO2013038373, WO2013038376, WO2013038381, WO2013038386, and WO2013038390,” [cited by applicant]
Notman, N. (2016) “2Heavy drugs gaining momentum” [online] Retrieved from the internet: https://www.chemistryworld.com/features/2heavy-drugs-gaining-momentum/1010186.article, on Oct. 7, 2019. [cited by applicant]
Passarella, D. et al. (2001) “Cyclodimerization of indol-2-ylacetylenes. An example of intermolecular enyne-alkyne cycloaddition” [cited by applicant]
Pham, P. et al. (2011) “Photoredox Catalysis: A Mild, Operationally Simple Approach to the Synthesis of alpha-Trifluoromethyl Carbonyl Compounds” Angew. Chem. Int. Ed. 2011:50 6119-6122. [cited by applicant]
Pirali T, Serafini M, Cargnin S, Genazzani AA. “Applications of Deuterium in Medicinal Chemistry” J Med. Chem. 2019; 62(11): 5276-5297. [cited by applicant]
Qun, C. et al. “Synthesis of 3,3,3-trifluoro-2,2-dimethylpropionic acid”, Huaxue Shiji—Chemical Reagents, Beijing : Huaxue Huaxue Shiji Keji Qingbao Zhongxinzhan, CN, vol. 38, No. 4, Jan. 1, 2016 (Jan. 1, 2016), pp. 386… [cited by applicant]
Rosebraugh, C.J. (2015) “Highlights of Prescribing Information for Orkambi,” [online] Retrieved from the Internet: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206038Orig1s000lbl.pdf, on Aug. 24, 2017. [cited by applicant]
Rossiiskii terapeuticheskii spravochnik [Russian therapeutic reference book], second edition, ed. Acad. RAMS A.G. Chuchalina, M. 2008, p. 144. [cited by applicant]
Schmidt C. “First deuterated drug approved” Nat. Biotechnol. 2017, 35, 493-494. [cited by applicant]
Shih et al. (2010) “Pyrazole compound BPR1P0034 with potent and selective anti-influenza virus activity” Journal of Biomedical Science, 17:13. [cited by applicant]
Silverman, R. (2004) The Organic Chemistry of Drug Design and Drug Action, Elsevier, pp. 29-32. [cited by applicant]
Soloducho, J. (1989) “Synthesis of Some Pyrido [2,3-c][1,2,6]triazinone Derivatives” [cited by applicant]
Soloducho, J. et al. “Synthesis of Some Pyrido[3,2g][1,2,5]triazocine Derivatives,” [cited by applicant]
Table 2 : List of the mutations or SNP tested in this study (https://www.jmdjournal.org/cms/10.2353/jmoldx.2008.080056/attachment/2286a276-d0b2-4a8a-83f8-8273bef9a761/mmc1.doc). Accessed Jan. 25, 2021. [cited by applicant]
Tsong-Long H. et al. “Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3”, Bioorganic & Medicinal Chemistry, vol. 23, No. 5, Ja… [cited by applicant]
Tullis, E. et al. (2018) “Preliminary safety and efficacy of triple-combination CFTR modulator regimens,” Respirology, 23(51):33. [cited by applicant]
U.S. Appl. No. 17/880,720, filed Aug. 4, 2022, by Abela et al. [cited by applicant]
Uttamsingh, V. et al. (2016) “WS13.6 CTP-656 tablet confirmed superiority of pharmacokinetic profile relative to Kalydeco in Phase I clinical studies” [cited by applicant]
Venkatesh, S. et al. (2000) “Role of the development scientist in compound lead selection and optimization” [cited by applicant]
Verado, G. et al. (1999) “Reductive One Batch Synthesis of N-Substituted Pyrrolidines from Primary Amines and 2,5-Dimethoxytetrahydrofuran” [cited by applicant]
Vertex Pharmaceuticals, Inc. (Jul. 18, 2017) “Vertex Announces Positive Phase 1 & Phase 2 Data from Three Different Triple Combination Regimens in People with Cystic Fibrosis Who Have One F508del Mutation and One Minima… [cited by applicant]
Vertex Pharmaceuticals, Inc. (Mar. 2, 20178) “Two Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment Met Primary Endpoints with Statistically Significant Improvements in Lung Function (FEV1) in People Wit… [cited by applicant]
Vertex Pharmaceuticals, Inc. (Nov. 3, 2017) “Vertex announces presentations of data at North American Cystic Fibrosis Conference that Demonstrate Important Progress Toward Goal of Helping All People with CF,” Health and… [cited by applicant]
“Vertex Provides Update on Ongoing Phase 3 Program for VX-661 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis” (Aug. 15, 2016) Retrieved from the Internet: https://www.businesswire.com/news/home/20160… [cited by applicant]
Vodak, D. (2014) “Design and Development of HPMCAS-Based Spray-Dried Dispersions,” 303-322. [cited by applicant]
Wainwright, C.E. et al. (2015) “Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR,” [cited by applicant]
Walters et al. (2002) “Prediction of ‘drug-likeness’,” Advanced Drug Delivery Reviews, 54(3), 255-271. [cited by applicant]
Willson T. M. et al. (1996) “Bone targeted drugs 2. Synthesis of estrogens with hydroxyapatite affinity,” Bioorg. & Med. Chem. Lett., (6):1047-1050. [cited by applicant]
Winn, M. et al. (1993) “2-(Alkylamino)nicotinic Acid and Analogs. Potent Angiotensin II Antagonists” [cited by applicant]
Yarnell AT. “Heavy-Hydrogen Drugs Turn Heads, Again” Chemical & Engineering News 2009; 87(25), 36-39. [cited by applicant]